|
|
 |
|
Viewing report
|
|
|
|
Cubist Pharmaceuticals, Inc.: SWOT Analysis & Company Profile
Business Review, Sep 2010, Pages: 24
Synopsis
Business Review’s Cubist Pharmaceuticals, Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning Cubist Pharmaceuticals, Inc.’s business.
Business Review’s “Cubist Pharmaceuticals, Inc. SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (Cubist Pharmaceuticals, Inc.) for business intelligence requirements
- Studies and presents Cubist Pharmaceuticals, Inc.’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
Cubist Pharmaceuticals, Inc. (Cubist) is a leading biopharmaceutical company, engaged in the research, development and commercialization of drug products for the acute care environments. The company’s lead product, CUBICIN (daptomycin for injection), an intravenous antibiotic, developed and launched in the US accounted for majority of its revenues. CUBICIN is used in the treatment of complicated skin and skin structure infections, blood-stream infections and right-sided infective endocarditis. Also, the company is engaged in the development of pre-clinical programs which focus on the treatment of Gram-positive infections, Gram-negative infections, CDAD (Clostridium difficile-associated diarrhea), and HCV (Hepatitis C infections). Cubist is headquartered in Lexington, Massachusetts, the US.
|
|
|
|
